Exchange: OTC·Updated 02:44 PM EDT
NEXI logo

NEXI Neximmune Inc

$0.0001
$0.00
(0.00%)
Today
Mkt Cap$139.00
Vol12.00

About NEXI

NexImmune, Inc. is a clinical stage biotechnology company, which engages in the development of novel approach to immunotherapy designed to employ the body's own T cells to generate an antigen-specific cell-mediated immune response with curative potential for the patient. Its product candidates are NEXI-001 in acute myeloid leukemia, or AML, and NEXI-002 in multiple myeloma, or MM. The company was founded by Kenneth C. Carter, Jonathan Schneck, and Mathias Oelke on June 7, 2011 and is headquartered in Gaithersburg, MD.
51

Neutral Sentiment

How do you feel about NEXI?

Advertisement|Remove ads.